# Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

> **NCT05383183** · PHASE4 · UNKNOWN · sponsor: **Daewoong Bio Inc.** · enrollment: 630 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Choline Alfoscerate 400mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05383183
- **Lead sponsor:** Daewoong Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-20
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-09
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383183, "Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05383183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*